Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells - PubMed
- ️Wed Jan 01 2014
. 2014 Feb 1;74(3):705-15.
doi: 10.1158/0008-5472.CAN-13-1342. Epub 2013 Dec 23.
Claire Germain, Thi Kim Duy Vo-Bourgais, Audrey Lupo, Christophe Klein, Samantha Knockaert, Luc de Chaisemartin, Hanane Ouakrim, Etienne Becht, Marco Alifano, Pierre Validire, Romain Remark, Scott A Hammond, Isabelle Cremer, Diane Damotte, Wolf-Herman Fridman, Catherine Sautès-Fridman, Marie-Caroline Dieu-Nosjean
Affiliations
- PMID: 24366885
- DOI: 10.1158/0008-5472.CAN-13-1342
Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells
Jérémy Goc et al. Cancer Res. 2014.
Abstract
Tumor-infiltrating T cells, particularly CD45RO(+)CD8(+) memory T cells, confer a positive prognostic value in human cancers. However, the mechanisms that promote a protective T-cell response in the tumor microenvironment remain unclear. In chronic inflammatory settings such as the tumor microenvironment, lymphoid neogenesis can occur to create local lymph node-like structures known as tertiary lymphoid structures (TLS). These structures can exacerbate a local immune response, such that TLS formation in tumors may help promote an efficacious immune contexture. However, the role of TLS in tumors has yet to be investigated carefully. In lung tumors, mature dendritic cells (DC) present in tumor-associated TLS can provide a specific marker of these structures. In this study, we evaluated the influence of TLS on the characteristics of the immune infiltrate in cohorts of prospective and retrospective human primary lung tumors (n = 458). We found that a high density of mature DC correlated closely to a strong infiltration of T cells that are predominantly of the effector-memory phenotype. Moreover, mature DC density correlated with expression of genes related to T-cell activation, T-helper 1 (Th1) phenotype, and cytotoxic orientation. Lastly, a high density of TLS-associated DC correlated with long-term survival, which also allowed a distinction of patients with high CD8(+) T-cell infiltration but a high risk of death. Taken together, our results show how tumors infiltrated by TLS-associated mature DC generate a specific immune contexture characterized by a strong Th1 and cytotoxic orientation that confers the lowest risk of death. Furthermore, our findings highlight the pivotal function of TLS in shaping the immune character of the tumor microenvironment, in promoting a protective immune response mediated by T cells against cancer.
Similar articles
-
Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, Belicova L, Praznovec I, Halaska MJ, Brtnicky T, Salkova E, Rob L, Kodet R, Goc J, Sautes-Fridman C, Fridman WH, Ryska A, Galluzzi L, Spisek R, Fucikova J. Truxova I, et al. J Immunother Cancer. 2018 Dec 4;6(1):139. doi: 10.1186/s40425-018-0446-3. J Immunother Cancer. 2018. PMID: 30526667 Free PMC article.
-
Schweiger T, Berghoff AS, Glogner C, Glueck O, Rajky O, Traxler D, Birner P, Preusser M, Klepetko W, Hoetzenecker K. Schweiger T, et al. Clin Exp Metastasis. 2016 Oct;33(7):727-39. doi: 10.1007/s10585-016-9813-y. Epub 2016 Jul 23. Clin Exp Metastasis. 2016. PMID: 27449756 Free PMC article.
-
Chelvanambi M, Fecek RJ, Taylor JL, Storkus WJ. Chelvanambi M, et al. J Immunother Cancer. 2021 Feb;9(2):e001906. doi: 10.1136/jitc-2020-001906. J Immunother Cancer. 2021. PMID: 33526609 Free PMC article.
-
Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J, Banerjee A. Reiser J, et al. J Immunol Res. 2016;2016:8941260. doi: 10.1155/2016/8941260. Epub 2016 May 22. J Immunol Res. 2016. PMID: 27314056 Free PMC article. Review.
-
Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.
Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautès-Fridman C. Dieu-Nosjean MC, et al. Immunol Rev. 2016 May;271(1):260-75. doi: 10.1111/imr.12405. Immunol Rev. 2016. PMID: 27088920 Review.
Cited by
-
Murphy RM, Tasoulas J, Porrello A, Carper MB, Tsai YH, Coffey AR, Kumar S, Zeng PY, Schrank TP, Midkiff BR, Cohen S, Salazar AH, Hayward MC, Hayes DN, Olshan A, Gupta GP, Nichols AC, Yarbrough WG, Pecot CV, Amelio AL. Murphy RM, et al. Cancer Res Commun. 2022 Sep;2(9):987-1004. doi: 10.1158/2767-9764.crc-21-0135. Epub 2022 Sep 15. Cancer Res Commun. 2022. PMID: 36148399 Free PMC article.
-
Zhang WH, Wang WQ, Han X, Gao HL, Xu SS, Li S, Li TJ, Xu HX, Li H, Ye LY, Lin X, Wu CT, Long J, Yu XJ, Liu L. Zhang WH, et al. J Immunother Cancer. 2020 Oct;8(2):e001188. doi: 10.1136/jitc-2020-001188. J Immunother Cancer. 2020. PMID: 33055204 Free PMC article.
-
Cai D, Wang X, Yu H, Bai C, Mao Y, Liang M, Xia X, Liu S, Wang M, Lu X, Du J, Shen X, Guan W. Cai D, et al. Clin Transl Immunology. 2024 Feb 5;13(2):e1489. doi: 10.1002/cti2.1489. eCollection 2024. Clin Transl Immunology. 2024. PMID: 38322490 Free PMC article.
-
CD4+ T cells in antitumor immunity.
Montauti E, Oh DY, Fong L. Montauti E, et al. Trends Cancer. 2024 Oct;10(10):969-985. doi: 10.1016/j.trecan.2024.07.009. Epub 2024 Sep 5. Trends Cancer. 2024. PMID: 39242276 Review.
-
Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies.
N J, J T, Sl N, Gt B. N J, et al. Oncoimmunology. 2021 Mar 29;10(1):1900508. doi: 10.1080/2162402X.2021.1900508. Oncoimmunology. 2021. PMID: 33854820 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials